Obtaining pure cell types from mixed cell populations continues to be a significant obstacle in the fields of stem cell biology and regenerative medicine.
Stanford Scientists have developed an innovative approach that enhances the antitumor efficacy of CAR T cells by overexpressing Adenosine Deaminase 1 (ADA), an enzyme responsible for metabolizing adenosine into inosine, to attenuate the immunosuppressive tumor microenvironment
Stanford researchers in the Wu Lab have developed hypoallergenic and immunogenic induced pluripotent stem cells that could be used as a cancer treatment or prophylactic.
This invention is an innovative breakthrough in cancer radiotherapy, offering a cutting-edge solution to address the challenges of radio-resistant and immunosuppressive tumors.
Researchers at Stanford have created ligand-induced dimerization activating RNA editing (LIDAR), a versatile molecular sensor that turns the presence of a ligand into translation of an output protein.
Stanford researchers have developed an expanded catalog of compact transcription effector domains and fused them onto DNA binding domains to engineer synthetic transcription factors.
Stanford researchers have developed a method to activate, cryopreserve, and thaw T regulatory (Tregs) cells that preserves their viability, phenotype and function.
Researchers at Stanford University have developed a novel method for the first time to generate cardiac pericytes from human induced pluripotent stem cells that closely resemble primary cells.
Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents.
Researchers at Stanford have developed a novel cell-free stem cell derived extracellular vesicle (EV) therapy powered by pulsed focused ultrasound (pFUS) that enhances its therapeutic and bioenergetic effect.
A major barrier in CAR-T cell therapies has been T cell exhaustion, which affects the durability and effectiveness of treatments, particularly for solid tumors.
Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.